Safety and Effectiveness on Domestic Hydrogen Clopidogrel in Perioperative Patients with Carotid Angioplasty and Stenting

Xiao-yan YU,Guang-xin DUAN,Wen-peng LIU,Jia-ping XU,Ji-jun SHI,Chun-yuan ZHANG,Guo-dong XIAO,Yong-jun CAO
DOI: https://doi.org/10.3969/j.issn.1009-881X.2015.01.006
2015-01-01
Abstract:Objective To observe safety and effectiveness of domestic hydrogen clopidogrel (Tai-jia) in perioperative patients with carotid angioplasty and stenting (CAS).Methods20 patients who would undergo CAS were enrolled in this study. All patients were given Tai-jia at a dose of 75 mg per day for at least 7 days prior to the operation, followed by 75 mg per day for 3 months. All the participants received aspirin at a dose of 75 mg during the study period. Cardio-cerebrovascular events and side effects were observed during the 3-month follow-up period.Results Of 20 patients enrolled, 24 stents were placed. The successful rate of operation was 100%. There were statistically signifi cant differences in FBG, LDL-C, CRP and Fg between the origin and end of the follow-up period (P<0.05). However, no signifi cant differences in white blood cell counts, serum creatinine, platelet counts, ALT and AST; In addition, there were statistically significant differences in NIHSS score (8.64±2.22 vs 4.54±2.78,P=0.004), and most patients recovered well at the end of the follow-up period (mRS 1.60±0.78, mRS≤2, 80%). 1 case was defi ned as TIA during the perioperative period. 2 cases of mild liver dysfunction and 1 case of itch were found during the study period. There were no cardio-cerebrovascular events and adverse drug reactions.Conclusion The safety and effectiveness of domestic hydrogen clopidogrel (Tai-jia) are satisfactory in perioperative patients with CAS, and the combination antiplatelet therapy of Tai-jia with aspirin can be used in perioperative period of CAS.
What problem does this paper attempt to address?